Business Wire

SMOORE

30.9.2021 14:23:06 CEST | Business Wire | Press release

Share
FEELM Reinforces its Commitment to Innovations in Atomization Technology at 2021 UK Media Day

SMOORE, a global leader in offering vaping technology solutions, today announced that its flagship atomization tech brand, FEELM, hosts 2021 UK Media Day at Silverstone Circuit. At the Media Day, Chief Scientist of SMOORE, Dr. Shi Zhiqiang, has reinforced FEELM’s commitment to innovations in atomization technology and affirmed that atomization coil is the key to the vape product performance and vaping experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005566/en/

As the flagship tech brand belonging to SMOORE, FEELM specializes in the development and manufacturing of high-quality closed pod vapes driven by its innovative FEELM coil.

FEELM coil technology features instant and high efficiency of atomization, smooth and pure taste until the last puff, smooth and delicate vapor, authentic flavor, and high nicotine delivery efficiency.

In 2019, FEELM launched the “FEELM Inside” global technology authentication trademark, as a symbol of excellent vaping experience for users. Today, the “FEELM inside” symbol is on the closed system pods of market-leading vaping brands around the world, such as RELX, NJOY, HAKA, HEXA, and VAPO.

“With the global launch of FEELM in 2016, FEELM has a significant impact on the research and manufacturing of closed vaping products, changing the global vaping industry landscape. The ‘FEELM inside’ symbol today is widely recognized by our partners and consumers as a certification of our commitment to quality, authenticity and high-quality vaping experience,” said Dr. Zhiqiang Shi, Chief Scientist of SMOORE. “Our Group has also made satisfying inroads in the research and development of medical and healthcare vaping products, with more than 1,000 scientists and experts from different backgrounds.”

Moreover, FEELM has adopted the industry’s first fully automated closed pod production line in 2019, realizing zero-staff inspection of product quality. To date, the productivity of a single line has reached a record high of 7,200 standard vaporizers per hour, and the annual production capacity of FEELM has surpassed three billion pieces.

Committed to SMOORE’s mission of “atomization making life better," FEELM has launched the world’s first taste evaluation model in December 2020. It covers four dimensions and 51 indexes, establishing a scientific system to evaluate vaping tastes. Moving forward, FEELM will also develop a Global Vape Flavor Map, by virtue of its global consumer base and extensive research on consumer behaviors.

As the world’s largest vaping device manufacturer in terms of revenue, SMOORE has accounted for 18.9% of the total global market share in 2020, according to Frost & Sullivan.

About FEELM:

FEELM is a flagship atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high-quality atomization devices driven by FEELM coil. The “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world.

About SMOORE:

SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye